HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

12 MONTH VULVAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copy of the 6 month CRF when completing this 12 month CRF: please complete any additional treatment details that were not captured at 6 months (for example, additional treatments, or end dates of those ongoing at 6 months)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address HORIZONS@soton.ac.uk
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

©2025. This work is openly licensed by CC BY-NC-SA

Participant's Study ID / /					
Participant's date of birth	у у у у				
Has the participant had any genetic tests f	or inherited cancers? (please tic	k one box)			
Yes (already recorded in previous CRF)					
Yes (but not recorded in previous CRF)					
No					
Unknown					
please provide some information about th completing the table(s) below	e participant's other genetic test((s) by			
Name of genetic test for cancer (1)	Result of genetic test				
	Positive				
	Negative				
	Ambiguous/uncertain				
	Awaiting result				
	Unknown				
Name of genetic test for cancer (2)	Result of genetic test				
	Positive				
	Negative				
	Ambiguous/uncertain				
	Awaiting result				
	Unknown				

Participant's Study ID / /	
Has the participant developed any NEW co-morbidities (which were not rethe baseline or 6 month CRF)? (please tick all that apply) in the tables beloverleaf)	
Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other	
chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Participant's Study ID / /
Participant's new co-morbidities continued
Clinical diagnosis of depression
Psychiatric Diagnosis (e.g. schizophrenia, bipolar disorder)
Osteoarthritis
Rheumatoid Arthritis
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)
HIV/AIDS
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)
Morbid Obesity
Other (please give details)
Other (please give details)
Other (please give details)
s the participant pre or post menopause? (please tick one box)
Pre menopause
Post menopause
Unknown

What treat	ment's Study ID ments has the participa ALL that apply and write ny treatments which we	e details in	the spaces provi	ded. Please add	end
Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Neo-adjuvant chemotherapy	Drug(s), please give details		/ / 20	// 20	
	Neo-adjuvant chemotherapy nu	mber of cycle	s, please enter on line		
Neo-adjuvant adiotherapy	External radiotherapy		/ / 20	/ / 20	
	Number of radiotherapy fraction	ns, please ente	er on line	•	
	Dose for each radiotherapy frac	tion please en	ter on line		
Surgery	Sentinel lymph node biopsy		// 20		
	Groin/inguinal lymph node dissection		// 20		
	Radical wide local excision / Wide local excsion		// 20		
	Radical partial vulvectomy / Partial vulvectomy		// 20		
	Radical vulvectomy		/ / 20		
	Pelvic exenteration		// 20		
	Vulval reconstruction		/ / 20		

Plastics surgery (please describe)

Other surgery (please describe)

Participant's Study ID		/		/			

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat - ment (if fin- ished) (dd/mm/yyyy)	If course of treat - ment was not completed as planned, please give a reason why		
Adjuvant Chemo-	Cisplatin		// 20	// 20			
therapy or Chemoradiation	Fluorouracil (5-FU)		// 20	// 20			
(please tick all that apply and give details for any radiotherapy	Mitomycin		/ / 20	// 20			
below)	Carboplatin		// 20	// 20			
	Paclitaxel/Taxol		// 20	// 20			
	Capcitabine		/ / 20	// 20			
	Other (please describe below):		// 20	// 20			
	Chemotherapy number of cycles, please enter on line						
Radiotherapy	External radiotherapy		// 20	// 20			
	Number of radiotherapy fractions, please enter on line						
	Dose for each radiotherapy fraction please enter on line						
	Brachytherapy		// 20				
	Number of radiotherapy fractions, please enter on line						
	Dose for each radiotherapy fraction please enter on line						
Other	Other treatment e.g. clinical trial treatment (please describe)		// 20	// 20			
Other	Dose for each radiotherapy Other treatment e.g. clinical trial treatment		ase enter on line				

Participant's Study ID / / /
Has the participant had a local recurrence of their vulval cancer? (please tick one box) Yes No Unknown
If the participant has had a local recurrence, on what date was the recurrence diagnosed?
Since the participant's diagnosis of vulval cancer, has there been any evidence of distant metastatic disease? (please tick one box)
Yes No Unknown
If you have answered "yes" to the above question, on what date was the metastat disease diagnosed:
Please provide details of the site(s) of distant metastatic disease:
Yes No Unknown
If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in Name of clinical trial

Participant's Study ID /					
Since the participant's diagnosis of vulval canother new primary cancer? (please tick o	•	1			
Yes No	Unknown				
If you answered "yes" to the above questing about the participant's new cancer diagno					
Type of cancer					
Date of diagnosis// 20					
Treatment received	Treatment received				
Date treatment ended (if finished)	Date treatment ended (if finished) / / 20				
What type of follow-up care is the partici	pant receiving? (please tick ONE box)				
Routine/regular hospital clinic based follow-up (medical or nurse led, face-to-face or by telephone)					
Primary care based follow-up					
Patient initiated follow-up (also known a (PTFU), open access follow-up, or suppor					
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?					

Participant's Study ID / /
Has the participant been referred to any of the following services and/or had a Holistic Needs Assessment? (please tick all that apply)
Participant has been referred to palliative care services
Participant has been referred to psychological services If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)
Participant has been referred to community services
Participant has been referred for treatment related problems (e.g. urology, gastroenterology) If ticked, please provide more details below:
Participant has had an HNA (holistic needs assessment)
If the participant has died please give the date and cause of death: Participant's date of death d d / m m / y y y y Cause of participant's death
1) a)
1) b)
1) c)
2)
Cause of death not known
Please add your name and signature and the date that you completed this CRF
Name Signature
Date CRF completed